Comments on EFSA's opinion about the health claim "improvement of bowel function" for hydroxyanthracenic derivatives.
Laboratoire de Pharmacognosie, CNRS UMR 8638, UFR Pharmacie, Univ. Paris René-Descartes, France.
Sabrina
S
Boutefnouchet
Laboratoire de Chimie des Substances Naturelles, CNRS UMR 8076 BioCIS, UFR Pharmacie, Université Paris-Sud, France. Electronic address: pierre.champy@u-psud.fr.
Pierre
P
Champy
Groupe Substances Naturelles, EA 4481, UFR Pharmacie, Université Lille 2 Droit et Santé, France.
Thierry
T
Hennebelle
Laboratoire de Chimie des Substances Naturelles, CNRS UMR 8076 BioCIS, UFR Pharmacie, Université Paris-Sud, France.
Alexandre
A
Maciuk
D000367:Age Factors; D003248:Constipation / Q000178:diet therapy*; D019587:Dietary Supplements; D005062:European Union; D005260:Female; D018565:Food-Drug Interactions; D006801:Humans; D054368:Laxatives / Q000009:adverse effects / Q000627:therapeutic use; D007880:Legislation, Drug / Q000458:organization & administration; D007881:Legislation, Food / Q000458:organization & administration; D010946:Plants, Medicinal / Q000009:adverse effects*; D011247:Pregnancy
D054368:Laxatives